单、双相抑郁障碍患者血浆神经肽Y及P物质水平的对比研究
|
摘要
目的：探讨血浆神经肽Y(NPY)及P物质(SP)水平在单、双相抑郁障碍发病机制中的作用及单、双相抑郁障碍患者血浆NPY及SPP水平差异。
方法：共有35名单相抑郁障碍患者、38名双相抑郁障碍患者及35名健康对照者参加研究,所有参研者均以M.I.N.I.简明国际神经精神障碍访谈检查进行结构化临床会晤,以MDQ及HCL-32筛查患者既往心境状况,以一般状况问卷、HAMD-17、HAMA及Young躁狂量表评定患者的一般状况及症状严重程度。采用ELISA法检查血浆NPY及SP水平。
结果：1.单抑郁障碍较之双相抑郁障碍,起病年龄晚、单次抑郁发作病程长、焦虑症状及躯体化症状较明显、抑郁症状严重、忧郁特征明显,但发作次数较少。
2.单相抑郁障碍组和双相障碍组血浆NPY水平低于对照组(5.838±1.793、5.951±2.148 v.s 8.071±3.224,P<0.05),SP水平高于对照组(6.239±2.617、5.784±1.498 V.S 4.081±1.540,P<0.05),差异有统计学意义,但单、双相抑郁障碍组之间NPY及SP水平差异没有统计学意义(P>0.05)。
3.患者组间男、女性患者血浆NPY水平(6.030±1.853 V.s 5.789±2.083,P=0.624)及SP水平(5.766±1.741v.s 6.192±1.932,P=0.351)没有明显差异。
4.无自杀风险组、低自杀风险组、中度自杀风险组及高自杀风险组患者的血浆NPY(5.418±2.624、6.099±1.744、6.172±1.721及5.716±2.703)及SP水平(5.101±1.871、6.669±1.744、5.708±1.789及6.054±0.859)差异无统计学意义(P>0.05)。
5.重度抑郁发作组与中度抑郁发作组血浆NPY水平差异无统计学意义(5.889±1.910 v.s5.904±2.06,P>0.05)；重度抑郁发作组血浆SP水平明显高于中度抑郁发作组,差异有统计学意义(6.498±1.863 v.s5.519±1.725,P<0.05)。
6.复发性抑郁发作组与首发性抑郁发作组血浆NPY水平无明显差异(6.271±1.88 v.s 5.307±2.000,P>0.05),但复发性抑郁发作组SP水平较首发性抑郁发作组明显增高,差异有统计学意义(6.341±1.890 v.s 5.466±1.676,P<0.05)
7.患者按焦虑水平分为有明显焦虑症状组、中度焦虑水平组及轻度焦虑水平组,三组间血浆NPY(6.009±1.754、6.020±2.206 v.s 5.488±1.881,P>0.05)及SP水平(5.980±1.915、6.141±2.045 v.s5.763±1.367,P>0.05)差异没有统计学意义。
8.患者血浆NPY与性别、年龄、发病年龄、总病程、单次发作病程、HAMA总分及HAMD总分为及各因子分之间没有明显相关性；血浆SP水平与睡眠障碍因子存在明显相关(R=0.328,P=0.007)
结论：本研究首次对比分析UDD、BDD及健康对照者的血浆NPY及SP水平,结果提示：
1.NPY及SP参与单、双相抑郁障碍的发病机制,单、双相抑郁障碍在NPY及SP方面的发病机制是相似的,血浆NPY及SP物质水平尚不能作为单、双相抑郁障碍鉴别诊断的生物学标志。
2.抑郁发作不同亚型的NPY功能紊乱相似,但重性抑郁发作及复发性抑郁发作患者SP能神经功能紊乱更为严重。
3.睡眠障碍是影响单、双相抑郁障碍患者血浆SP水平的主要因素。
Objective:To explore the effects of plasma neuropeptide Y and substance P in the etiology of unipolar and bipolar depressive disorders, and to explore the difference in the plasma neuropeptide Y and substance P levels between patients with unipolar and bipolar depressive disorders.
Methods:35 patients with unipolar depressive disorders(UDD),38 patients with bipolar depressive disorder(BDD) and 35 controls were recruited in the study, and interviewed by the MINI International Neuropsychiatric terview for DSM-Ⅳby a senior psychiatrist at the department of psychiatry in the First Affiliated Hospital of Jinan University. Hamilton Depression Scale, Hamilton Anxiety Scale and Young Mania Rating Scale were used to assess the severity of clinical symptoms. Mood Disorder Questionnaire (MDQ)and The 32-item Hypomania Symptom Check List (HCL-32) were used to explore the history of Manic/hypomanic episode. The plasma substance P and neuropeptide Y levels were determined with the enzyme linked immunosorbent assay.
Results:1.Compared with BDD group, the UDD group presented the first depression onset at older ages,longer duration of single episodes of depression, more anxiety symptoms, somatization symptoms and melancholic features, more severe depressive symptoms, but less relapse times.
2. The plasma neuropeptide Y levels were significantly lower in the patients with UDD and BDD than those in the controls (5.838±1.793.5.951±2.148V.S. 8.071±.224, P<0.05).The plasma substance P levels were significantly higher in the patients with UDD and BDD than those in the controls (6.239±2.617、5.784±1.498 V.S4.081±1.540, P<0.05), but there was no significant difference in plasma neuropeptide Y and substance P levels between UDD group and BDD group.(P> 0.05)
3. There was no significant difference in plasma neuropeptide Y (6.030±1.853v.s5.789±2.083, P=0.624) and substance P levels (5.766±1.741 v.s6.192±1.932, P=0.351) between female patients and male ones.
4. Plasma neuropeptide Y levels(5.101±1.871,6.669±1.744,5.708±1.789 and 6.054±0.859) and substance P levels (5.418±2.624,6.099±1.744,6.172±1.721 and 5.716±2.703) showed no significant difference (P> 0.05) among no suicide risk group, low suicide risk group, moderate suicide risk group and high suicide risk group.
5. There was no significant difference in plasma neuropeptide Y levels between severe depressive episode group and the moderate group (5.889±1.910v.s5.904±2.06, P> 0.05); the plasma substance P levels was higher in severe depressive episode group than those in moderate depressive episode group, the difference was statistically significant (6.498±1.863v.s5.519±1.725, P<0.05).
6. The neuropeptide Y concentrations in the patients with recurrent depression were similar to those ones with first-episode depression (6.271±1.88v.s5.307±2.000, P>0.05).The plasma substance P levels were higher than that in first-episode depression patients (6.341±1.890v.s 5.466±1.676,P<0.05).
7. The plasma levels of neuropeptide Y and substance P were similar among severe anxiety level group, moderate anxiety level group and mild anxiety group. The difference was no statistically significant
8. The plasma neuropeptide Y levels had no correlation with sex, age, age of first depression onset, total duration, duration of single attack, HAMA total score and HAMD total score and factor scores. The plasma substance P levels were significantly correlated with sleep disturbance factors in HAMD,but had no correlation with other factors.
Conclusion:The plasma neuropeptide Y and substance P levels in patients with UDD and BDD were first detected and compared, and the results demonstrated that:
1.The change of substance P and neuropeptide Y may be involved in the pathogenesis or pathophysiology of UDD and BDD, the abnormalities wre remarkably similar in BDD and UDD. There is no evidence shows that the substance P and neuropeptide Y could been useful biomarkers for differential diagnosis of BDD and UDD.
2. Different subtypes of depressive episode were similar in the NPY dysfunction side,but SP dysfunction was more serious in the major depressive episode group and recurrent depressive episode group than moderate depressive episode and firstdepressive episode group.
3. Sleep disturbance was the main factor that affected the plasma substance P levels in patients with UDD and BDD.
方法：共有35名单相抑郁障碍患者、38名双相抑郁障碍患者及35名健康对照者参加研究,所有参研者均以M.I.N.I.简明国际神经精神障碍访谈检查进行结构化临床会晤,以MDQ及HCL-32筛查患者既往心境状况,以一般状况问卷、HAMD-17、HAMA及Young躁狂量表评定患者的一般状况及症状严重程度。采用ELISA法检查血浆NPY及SP水平。
结果：1.单抑郁障碍较之双相抑郁障碍,起病年龄晚、单次抑郁发作病程长、焦虑症状及躯体化症状较明显、抑郁症状严重、忧郁特征明显,但发作次数较少。
2.单相抑郁障碍组和双相障碍组血浆NPY水平低于对照组(5.838±1.793、5.951±2.148 v.s 8.071±3.224,P<0.05),SP水平高于对照组(6.239±2.617、5.784±1.498 V.S 4.081±1.540,P<0.05),差异有统计学意义,但单、双相抑郁障碍组之间NPY及SP水平差异没有统计学意义(P>0.05)。
3.患者组间男、女性患者血浆NPY水平(6.030±1.853 V.s 5.789±2.083,P=0.624)及SP水平(5.766±1.741v.s 6.192±1.932,P=0.351)没有明显差异。
4.无自杀风险组、低自杀风险组、中度自杀风险组及高自杀风险组患者的血浆NPY(5.418±2.624、6.099±1.744、6.172±1.721及5.716±2.703)及SP水平(5.101±1.871、6.669±1.744、5.708±1.789及6.054±0.859)差异无统计学意义(P>0.05)。
5.重度抑郁发作组与中度抑郁发作组血浆NPY水平差异无统计学意义(5.889±1.910 v.s5.904±2.06,P>0.05)；重度抑郁发作组血浆SP水平明显高于中度抑郁发作组,差异有统计学意义(6.498±1.863 v.s5.519±1.725,P<0.05)。
6.复发性抑郁发作组与首发性抑郁发作组血浆NPY水平无明显差异(6.271±1.88 v.s 5.307±2.000,P>0.05),但复发性抑郁发作组SP水平较首发性抑郁发作组明显增高,差异有统计学意义(6.341±1.890 v.s 5.466±1.676,P<0.05)
7.患者按焦虑水平分为有明显焦虑症状组、中度焦虑水平组及轻度焦虑水平组,三组间血浆NPY(6.009±1.754、6.020±2.206 v.s 5.488±1.881,P>0.05)及SP水平(5.980±1.915、6.141±2.045 v.s5.763±1.367,P>0.05)差异没有统计学意义。
8.患者血浆NPY与性别、年龄、发病年龄、总病程、单次发作病程、HAMA总分及HAMD总分为及各因子分之间没有明显相关性；血浆SP水平与睡眠障碍因子存在明显相关(R=0.328,P=0.007)
结论：本研究首次对比分析UDD、BDD及健康对照者的血浆NPY及SP水平,结果提示：
1.NPY及SP参与单、双相抑郁障碍的发病机制,单、双相抑郁障碍在NPY及SP方面的发病机制是相似的,血浆NPY及SP物质水平尚不能作为单、双相抑郁障碍鉴别诊断的生物学标志。
2.抑郁发作不同亚型的NPY功能紊乱相似,但重性抑郁发作及复发性抑郁发作患者SP能神经功能紊乱更为严重。
3.睡眠障碍是影响单、双相抑郁障碍患者血浆SP水平的主要因素。
Objective:To explore the effects of plasma neuropeptide Y and substance P in the etiology of unipolar and bipolar depressive disorders, and to explore the difference in the plasma neuropeptide Y and substance P levels between patients with unipolar and bipolar depressive disorders.
Methods:35 patients with unipolar depressive disorders(UDD),38 patients with bipolar depressive disorder(BDD) and 35 controls were recruited in the study, and interviewed by the MINI International Neuropsychiatric terview for DSM-Ⅳby a senior psychiatrist at the department of psychiatry in the First Affiliated Hospital of Jinan University. Hamilton Depression Scale, Hamilton Anxiety Scale and Young Mania Rating Scale were used to assess the severity of clinical symptoms. Mood Disorder Questionnaire (MDQ)and The 32-item Hypomania Symptom Check List (HCL-32) were used to explore the history of Manic/hypomanic episode. The plasma substance P and neuropeptide Y levels were determined with the enzyme linked immunosorbent assay.
Results:1.Compared with BDD group, the UDD group presented the first depression onset at older ages,longer duration of single episodes of depression, more anxiety symptoms, somatization symptoms and melancholic features, more severe depressive symptoms, but less relapse times.
2. The plasma neuropeptide Y levels were significantly lower in the patients with UDD and BDD than those in the controls (5.838±1.793.5.951±2.148V.S. 8.071±.224, P<0.05).The plasma substance P levels were significantly higher in the patients with UDD and BDD than those in the controls (6.239±2.617、5.784±1.498 V.S4.081±1.540, P<0.05), but there was no significant difference in plasma neuropeptide Y and substance P levels between UDD group and BDD group.(P> 0.05)
3. There was no significant difference in plasma neuropeptide Y (6.030±1.853v.s5.789±2.083, P=0.624) and substance P levels (5.766±1.741 v.s6.192±1.932, P=0.351) between female patients and male ones.
4. Plasma neuropeptide Y levels(5.101±1.871,6.669±1.744,5.708±1.789 and 6.054±0.859) and substance P levels (5.418±2.624,6.099±1.744,6.172±1.721 and 5.716±2.703) showed no significant difference (P> 0.05) among no suicide risk group, low suicide risk group, moderate suicide risk group and high suicide risk group.
5. There was no significant difference in plasma neuropeptide Y levels between severe depressive episode group and the moderate group (5.889±1.910v.s5.904±2.06, P> 0.05); the plasma substance P levels was higher in severe depressive episode group than those in moderate depressive episode group, the difference was statistically significant (6.498±1.863v.s5.519±1.725, P<0.05).
6. The neuropeptide Y concentrations in the patients with recurrent depression were similar to those ones with first-episode depression (6.271±1.88v.s5.307±2.000, P>0.05).The plasma substance P levels were higher than that in first-episode depression patients (6.341±1.890v.s 5.466±1.676,P<0.05).
7. The plasma levels of neuropeptide Y and substance P were similar among severe anxiety level group, moderate anxiety level group and mild anxiety group. The difference was no statistically significant
8. The plasma neuropeptide Y levels had no correlation with sex, age, age of first depression onset, total duration, duration of single attack, HAMA total score and HAMD total score and factor scores. The plasma substance P levels were significantly correlated with sleep disturbance factors in HAMD,but had no correlation with other factors.
Conclusion:The plasma neuropeptide Y and substance P levels in patients with UDD and BDD were first detected and compared, and the results demonstrated that:
1.The change of substance P and neuropeptide Y may be involved in the pathogenesis or pathophysiology of UDD and BDD, the abnormalities wre remarkably similar in BDD and UDD. There is no evidence shows that the substance P and neuropeptide Y could been useful biomarkers for differential diagnosis of BDD and UDD.
2. Different subtypes of depressive episode were similar in the NPY dysfunction side,but SP dysfunction was more serious in the major depressive episode group and recurrent depressive episode group than moderate depressive episode and firstdepressive episode group.
3. Sleep disturbance was the main factor that affected the plasma substance P levels in patients with UDD and BDD.
引文
[1].The World Health Report 2001, Mental Health:New Undertanding, New Hope WHO, Geneva,2001.
[2]Angst J. The emerging epidemiology of hypomania and bipolar Ⅱ disorder.[J].J Affect Disord 1998;50(2-3):143-51.
[3]Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020:Global Burden of Disease Study[J].The Lancet,1997;349 (9064):1498-1504.
[4]Benazzi, F. High frequency of bipolar spectrum in outpatients with depression. [J].Can. J. Psychiatry 2004;49,279-280.
[5]Hirschfeld RM, Calabresse JR,Weissman MM, et al. Screening for BPD in the community.[J]. J Clin Psychiatry 2003;64(1):53-59.
[6]Heilig M, Widerlov E. Neurobiology and clinical aspects of neuropeptide Y. [J].Crit Rev Neurobiol.1995;9(2-3):115-36.
[7]Adrian TE, Allen JM, Bloom SR, et al.Neuropeptide Y distribution in human brain.[J]. Nature 1983;306(5943):584-586.
[8]. Gerald C, Walker MW, Criscione L, et al. A receptor subtype involved in neuropeptide-Y-induced food intake. [J].Nature 1996;382(6587):168-171.
[9]Heilig M, Widerlov E. Neuropeptide Y:an overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses. [J].Acta Psychiatr Scand 1990;82(2):95-114.
[10]Flood JF, Hernandez EN, Morley JE. Modulation of memory processing by neuropeptide Y. [J].Brain Research 1987;421(1-2):280-90.
[11]Redrobe JP, Dumont Y, St-Pierre JA, Quirion R. Multiple receptors for neuropeptide Y in the hippocampus:putative roles in seizures and cognition.[J]. Brain Research.1999;848(1-2):153-66.
[12]Colmers WF, Bleakman D. Effects of neuropeptide Y on the electrical properties of neurons. [J].Trends in Neuroscience.1994;17(9):373-9.
[13]Vezzani A, Sperk G, Colmers WF. Neuropeptide Y:emerging evidence for a functional role in seizure modulation.Trends in Neuroscience.1999;22(1):25-30.
[14]Small CJ, Morgan DG, Meeran K, Heath MM, Gunn I, Edwards CM, et al. Peptide analogue studies of the hypothalamic neuropeptide Y receptor mediating pituitary adrenocorticotrophic hormone release. Proceedings of the National Academy of Science USA.1997;94(21):11686-91.
[15]Catzeflis C, Pierroz DD, Rohner-Jeanrenaud F,et al. Neuropeptide Y administered chronically into the lateral ventricle profoundly inhibits both the gonadotropic and the somatotropic axis in intact adult female rats. Endocrinology 1993;132(1):224-34.
[16]Hashimoto H, Onishi H, Koide S,et al.Plasma neuropeptide Y in patients with major depressive disorder.[J].Neurosci Lett.1996;216(1):57-60.
[17]Heilig M, Murison R.Intracerebroventricular neuropeptide Y suppresses open field and home cage activity in the rat[J].Regulatory Peptides.1987;19(3-4):221-231.
[18]Heilig M.Murison R.Intracerebroventricular neuropeptideY protects against stress-induced gastric erosion in the rat. [J].European Journal of Pharmacology.1987;137(1):127-129.
[19]Tong Y, Dumont Y, Shen SH, Quirion R. Comparative developmental profile of the neuropeptide Y Y1 receptor gene and protein in the rat brain. [J].Molecular Brain Research.1997;48(2):323-32.
[20]Dumont Y, Fournier A, St-Pierre S, et al. Differential distribution of neuropeptide Y1 and Y2 receptors in the rat brain. [J] European Journal of Pharmacology.1990;191(3):501-3.
[21]Dumont Y, Fournier A, St-Pierre S,et al.. Autoradiographic distribution of [1251] [Leu31,Pro34]PYY and [125I]PYY-3-36 binding sites in the rat brain evaluated with two newly developed Y1 and T2 receptor radioligands. [J].Synapse,1996; 22(2):139-58.
[22]Kerkerian-Le Goff L, Forni C, et al. Intracerebroventricular administration of neuropeptide Y affects parameters of dopamine, glutamate and GABA activities in the rat striatum.[J]. Brain Res Bull.1992;28(2):187-193.
[23]Drumheller A, Bouali SM, Fournier A,et al. Neurochemical effects of neuropeptide Y (NPY) and NPY2-36.[J] Neuropeptides.1994;27(5):291-296.
[24]Gruber SH, Nomikos GG, Mathe AA. D-Amphetamine-induced increase in neurotensin and neuropeptide Y outflow in the ventral striatum is mediated via stimulation of dopamine D1 and D2/3 receptors.[J] J Neurosci Res.2002;69(1):133-139.
[25]Gruber SH, Mathe AA. Effects of typical and atypical antipsychotics on neuropeptide Y in rat brain tissue and microdialysates from ventral striatum.[J].J Neurosci Res.2000;61(4):458-463.
[26]Widerlov E, Lindstrom LH, Wahlestedt C, et al. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively [J]. Journal of Psychiatric Research.1988;22(1),69-79.
[27]Nikisch G, Mathe AA. CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy [J].European Psychiatry,2008; 23(5):356-359.
[28]Heilig M, Olof Zachrisson O, Thorsell A,et al. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism[J] Journal of Psychiatric Research,2004,38(2):113-121
[29]侯彩兰 贾福军 陈佐明等。重性抑郁症患者脑脊液中P物质、神经肽Y、5-羟色胺及去甲肾上腺素含量的研究[J].中华精神科杂志.2005；38(4)：199-201
[30]Widdowson PS, Ordway GA, Halaris AE. Reduced neuropeptide Y concentrations in suicide brain. [J].Neurochem.1992;59(1):73-80.
[31]Berrettini WH, Doran AR, Kelsoe J,,et al. Cerebrospinal fluid neuropeptide Y in depression and schizophrenia. [J].Neuropsychopharmacology.1987;1(1):81-83.
[32]Ordway GA, Stockmeier CA, Meltzer HY, et al. Neuropeptide Y in frontal cortex is not altered in major depression[J]. Journal of Neurochemistry.1995; 65(4):1646-1650.
[33]Frisch C, HankeJ, Kleineruschkamp S,et al. Positive correlation between the density of neuropeptide Y positive neurons in the amygdala and parameters of self-reported anxiety and depression in mesiotemporal lobe epilepsy patients. [J].Biol. Psychiatry.2009;66(5):433-440.
[34]Morgan CA, Rasmusson AM, Wang S, et al.NeuropeptideY, cortisol, and subjective distress in humans exposed to acute stress:replication and extension of previous report.[J] Biol. Psychiatry.2002;52 (2):136-142.
[35]Larsen PJ, Kristensen P. The neuropeptide Y (Y4) receptor is highly expressed in neurones of the rat dorsal vagal complex.[J] Brain Res. Mol. Brain Res.1997;48(1): 1-6
[36]Hashimoto H, Onishi H,Koide S, et al. Plasma neuropeptide Y in patients with major depressive disorder[J]. Neuroscience Letters.1996;216 (1):57-60
[37]陈松芳,吴志鹏,邵胜等。氟西汀对抑郁症患者血浆中P物质和神经肽Y的影响。[J]安徽医药.2008；12(7)：641-642
[38]杨斌,王有德,叶兰仙等。抑郁症患者血浆神经肽Y含量变化及其影响因素[J]中国临床康复.2006；10(46)：106-108
[39]Westrin A, Ekman R,skman-Bend L. Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y(NPY) plasma levels in mood disorder patients with a recent suicide attempt [J].European Neuropsychopharmacology.1999;9 (3):205-211
[40]Held K, Antonijevic I, Murck H, et al.Neuropeptide Y (NPY) shortens sleep latency but does not suppress ACTH and cortisol in depressed patients and normal controls[J].Psychoneuroendocrinology,2006; 31(1):100-107.
[41]Antonijevic IA, Murck H, Bohlhalter S, et al. Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men[J].Neuropharmacology,2000; 39(8):1474-1481.
[42]Sjoholm LK, Melas PA, Forsell Y, et al. PreproNPY Pro7 protects against depression despite exposure to environmental risk factors[J].Journal of Affective Disorders,2009;118,(1-3):124-130.
[43]Czermak C, Hauger R, Drevets WC, et al. Plasma NPY concentrations during tryptophan and sham depletion in medication-free patients with remitted depression [J].Journal of Affective Disorders,2008;110(3):277-281.
[44]Nilsson C, Karlsson G, Blennow K, et al. Differences in the neuropeptide Y-like immunoreactivity of the plasma and platelets of human volunteers and depressed patients.[J] Peptides.1996;17(3):359-62..
[45]Nikisch G., Agren H., Eap CB.,et al. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram [J].Int. J. Neuropsychopharmaco 1.2005; 8,(3):403-410.
[46]Widerlov, E., Heilig, M., Ekman, R., et al. Possible relationship between neuropeptide Y (NPY) and major depression:evidence from human and animal studies Nordic.[J]J. Psychiatry.1988;42,131-137.
[47]Olsson A., Regnell G, Traskman-Bendz L,et al. Cerebrospinal neuropeptide Y and substance P in suicide attempters during long-term antidepressant treatment.[J]. Eur. Neuropsychopharmacol.2004; 14(6):479-485.
[48]Redrobe JP, DumontY, Fournier,A, et al. Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test.[J]. Peptides.2005;26(8):1394-1400.
[49]Ishida H, Shirayama Y, Iwata M,et al.Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor. Hippocampus 2007;17(4):,271-280.
[50]Ruohonen ST, Savontaus E, Rinne P, et al. Stress-induced hypertension and increased sympathetic activity in mice overexpressing neuropeptide Y in noradrenergic neurons.[J] Neuroendocrinology.2009;89(3):,351-360.
[51]Jimenez-Vasquez PA, Zaida Diaz-Cabiale Z, Caber lotto L,et al.Electroconvulsive stimuli selectively affect behavior and neuropeptide Y (NPY) and NPY Y1 receptor gene expressions in hippocampus and hypothalamus of Flinders Sensitive Line rat model of depression [J] European neuropsychopharmacology.2007;17(4):298-308
[52]Obuchowicz E, Krysiak R, Herman ZS. Does neuropeptide Y (NPY) mediate the effects of psychotropic drug[J].Neuroscience and Biobehavioral Reviews.2004;28(6):595-610
[53]Kuromitsu J, Yokoi A, Kawai T, et al.Reduced neuropeptide Y mRNA levels in the frontal cortex of people with schizophrenia and bipolar disorder [J].Gene Expression Patterns.2001;1(1):17-21
[54]Caberlotto L, Hurd YL, Neuropeptide Y Y(1) and Y(2) receptor mRNA expression in the prefrontal cortex of psychiatric subjects. Relationship of Y(2) subtype to suicidal behavior. [J].Neuropsychopharmacology.2001;25(1):91-97.
[55]Zachrisson O, Mathe'AA, Stenfors C, et al. Region-specific effects of chronic lithium administration on neuropeptide Y and somatostatin mRNA expression in the rat brain. [J]Neurosci Lett 1995;194 (1-2):89-92.
[56]Harrison S, Geppetti P. Substance P. [J]. International Journal of Biochemistry and Cell Biology.2001;33,555-576.
[57]Ribeiro-da-Silva A, Hokfelt T. Neuroanatomical localisation of substance P in the CNS and sensory neurons. [J].Neuropep tides.2000;34 (5):256-271
[58]Richard Hargreaves. Imaging substance P recep tors(NK1) in the living human brain using positron emission tomography. [J]J clin Psychiatry,2002;63 (supp 111): 18-24
[59]Sergeyev V, Hokfelt T, Hurd Y. Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. [J].NeuroReport.1999;10(18):3967-3970.
[60]Hahn MK, Bannon MJ. Stress-induced C-fos expression in the rat locus coeruleus is dependent on neurokinin 1 receptor activation. [J]. Neuroscience.1999;94(4):1183-1188.
[61]Otsuka M., Yoshioka K. Neurotransmitter functions of mammalian tachykinins. [J]Physiol. Rev.1993;73 (2):229-308.
[62]Lieb K, Ahlvers K, Dancker K, et al. Effects of the neuropeptides substance P on sleep, mood, and neuroendocrine measures in healthy young men. [J].Neurop sychopharmacology.2002;27 (6):1041-1049
[63]Andersen ML, Nascimento DC, Machado RB et al. Sleep disturbance induced by substance P in mice[J] Behavioural Brain Research.2006; 167(2):212-218
[64]Teixeira, R.M., Santos A RS, Ribeiro SJ, et al. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behaviour in mice. [J].Eur. J. Pharmacol.1996;311(1):7-14
[65]Krase,W, Michael K,Hans-Ulrichet S. Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats. [J]Behav. Brain Res. 1994;63(1):81-88
[66]Kramer, M.S. Cutler N, Feighner J,et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors.[J]. Science.1998;281(5383): 1640-1645.
[67]Rupniak, N.M. et al. Comparison of the phenotype of NK1R-/-mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. [J]Behav. Pharmacol.2001;12(6-7):497-508
[68]Papp M, Vassout A, Gentsch C. The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats.[J]. Behav. Brain Res.2000; 115(1):19-23
[69]Varty, G.B.Cohen-willians ME,Morgan CA, et al.. The gerbil elevated plus-maze Ⅱ:anxiolytic-like effects of selective neurokinin NK1 receptor antagonists [J]Neuropsychopharmacology.2002; 27(3):371-379
[70]Rimon R., Greves L P., Nyberg, F., et al.. Elevation of substance P-like peptides in the CSF of psychiatric patients.[J]. Biological Psychiatry 1984,19(4):509-516.
[71]Geracioti TD, Carpenter LL, Owens, M.J, et al. Elevated cerebrospinal fluid substance P concentrations in post-traumatic stress disorder and major depression. [J] American Journal of Psychiatry.2006; 163 (4):637-643.
[72]Bondy B, Baghai TC, Minov C, et al. Substance P Serum Levels Are Increased in Major Depression:Preliminary Results[J].BIOLPSYCHIATRY.2003;53(6):538-542.
[73]Deuschle M, Peter Sander P, Inga Herpfer H, et al.Substance P in serum and cerebrospinal fluid of depressed patients:No effect of antidepressant treatment.[J]. Psychiatry Research.2005;136(1):1-6
[74]Carpenter LL, Bayat L, Moreno F, et al. Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy[J] Psychiatry Research. 2008;157(1-3):123-129
[75]Shirayama Y, Mitsushio H., Takashima M., et al. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat.[J].Brain Research.1996; 739(1-2):70-78.
[76]Martensson B, Nyberg S, Toresson G.,et al. Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid. [J] Acta Psychiatrica Scandinavica.1989;79(6):586-596.
[77]Lieb K,Walden J,Grunze H, et al. Serum levels of substance P and response to antidepressant pharmacotherapy. [J].Pharmacopsychiatry.2004;37(5):238-239.
[78]Burnet PW, Harrison PJ. Substance P (NK1) redeptors in the cingulate cortex in unipolar and biopolarmood disorder and schizophrenia. [J].Biol p sychiatry.2000;47 (1):80-83
[79]Freed AL, Audus KL, Lunte SM. Investigation of substance P transport across the blood-brain barrier. [J]Peptides.2002;23(1):157-165.
[80]Dunner DL. Clinical consequences of under-recognized bipolar spectrum disorder.[J].J Bipolar Disord.2003;5(6):456-464.
[81]Post RM, Leverich GS, NolenWA, et al. A reevaluation of the role of antidepressants in the treatment of bipolar depression:data from the Stanley Foundation Bipolar Network.[J] Bipolar Disord.2003;5(6):396-406.
[82]Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major dep ression and bipolar disorder [J]. JAMA,1996;276 (4):293-299.
[83]Benazzi F. Symptoms of depression as possible markers of bipolar Ⅱ disorder [J]. Prog Neurop sychopharmacol Biol Psychiatry,2006;30 (3):471-477.
[84]Weissman, M.M., Bland, R.C., Canino, GJ. Cross-sectional epidemiology of major depression and bipolar depression. [J] JAMA:The Journal of the American Medical Association.1996.;276 (4):293-299.
[85]Benazzi F. Challenging the unipolar-bipolar division:Does mixed depression bridge the gap? [J]. Neuro-Psychopharmacology & Biological Psychiatry.2007;31 (1):97-103.
[86]National Institute of Mental Health (NIMH). (1998). Genetics and mental disorders:Report of the NIMH genetics workgroup.Bethesda, MD7'NIMH publication number NIH-98-4268.
[87]Benazzi F. Family history validation of a definition of mixed depression[J]. Comprehensive Psychiatry.2005;46,(3):159-166
[88]Emilien G, Septien L, Brisard C, et al. Bipolar disorder:How far are we from a rigorous definition and effective management?[J] Neuro-Psychopharmacology & Biological Psychiatry.2007;31 (5):975-996.
[89]KelsoeJ R. Arguments for the genetic basis of the bipolar spectrum. [J].Journal of Affective Disorders.2003;73,(2):183-197.
[90]Benazzi F. Symptoms of depression as possible markers of bipolarⅡ disorder [J]. Prog Neurop sychopharmacology Biol Psychiatry.2006; 30 (3):471-477.
[91]Serretti A, Mandelli L, Lattuada E,et al. Clinical and demographic features of mood disorder subtypes.[J]. Psychiatry Res.2002;112(3):195-210.
[92]Baethge C, Baldessarini RJ, Freudenthal K, et al. Hallucinations in BPD: characteristics and comparison to unipolar depression and schizophrenia.[J]. Bipolar Disord.2005;7(2):136-45.
[93]Goldberg J F, Perlis R H, Bowden C L, et al. Manic Symptoms During Depressive Episodes in 1,380 Patients With Bipolar Disorder:Findings From the STEP-BD[J].Am J Psychiatry.2009;166(2):173-181.
[94]Benazzi F. Mixed dep ression:a clinicalmarker of bipolar-Ⅱ disorder [J]. Prog Neurop sychopharmacology Biol Psychiatry.2005;29 (2):267-274.
[95]Videbech P. PET measurements of brain glucose metabolism and blood flow in major depressive disorder:A critical review. [J] Acta Psychiatrica Scandinavica, 2000;101(1):11-20.
[96]Yurgelun-Todd DA, Gruber SA, Kanayama G.,et al. fMRI during affect discrimination in bipolar affective disorder. [J].Bipolar Disorders,2000;3,237-248.
[97]Koslow SH, Maas JW, Bowden CL,et al. CSF and urinary biogenic amines and metabolites in depression and mania. A controlled, univariate analysis. [J]Archives of General Psychiatry,1983;49(9),999-1010.
[98]Asberg M., Bertillsson L, Martensson B,et al. CSF monoamine metabolites in melancholia.[J]. Acta Psychiatrica Scandinavica,1984;69(3):201-219.
[99]Altshuler LL., Curran JG, Hauser P, et al. T2 hyperintensities in bipolar disorder:Magnetic resonance imaging comparison and literature meta-analysis. [J]American Journal of Psychiatry,1995;152,1139-1144.
[100]Ackenheil M. Neurotransmitters and signal transduction processes in bipolar affective disorders:A synopsis. [J]Journal of Affective Disorders,2001;62(1): 101-111.
[101]Barbini B, Colombo C, Benedetti F, et al. The unipolar-bipolar dichotomy and the response to sleep deprivation.[J]. Psychiatry Research,1998; 79(1):43-50.
[102]American Psychiatric Association,1994. Diagnostic and Statistical Manual of Mental Disorders,4th ed. American Psychiatric Association, Washington, DC.
[103]LecrubierY, Sheehan D,Weiller E,et al. The MINI International Neuropsychiatric terview (M.I.N.I.) a short diagnostic structured interview:reliability and validity according to the CIDI.[J]Eur Psychiatry,1997,12:224-231
[104]司天梅；舒良；党卫民等。简明国际神经精神访谈中文版的临床信效度。[J]中国心理卫生杂志.2009；23(7)：493-497.
[105]赵靖平；郑延平.Hamilton抑郁量表的信度和效度.[J]中国心理卫生杂志,1992：6(5)： 214-216
[106]Hirschfeld RMA,Williams JBW, Calabrese JR, et al. Development and validation of a screening instrument for bipolar spectrum disorder:The mood disorder questionnaire[J]. Am J Psychiatry,2000;157:1873-1875.
[107]杨海晨,廖春平,苑成梅等.中文版心境障碍问卷在双相Ⅰ型障碍中的应用[J].临床精神医学杂志.2009；9(1)：19-21.
[108][Ka-Fai Chung, Kwok-Chu Tso, Robert Ting-Yiu Chung.Validation of the Mood Disorder Questionnaire in the general population in Hong Kong[J] Comprehensive Psychiatry,2009;50(5):471-476.
[109]Vieta E, Moreno JS, A. Bulbena A,et al. Cross validation with the mood disorder questionnaire (MDQ) of an instrument for the detection of hypomania in Spanish:The 32 item hypomania symptom check list (HCL-32)[J]. Journal of Affective Disorders,2007;101(1-3):43-55
[110]Dotsch, Adelmann J, Englaro P, et al. Relation of leptin and neuropeptide Y in human blood and cerebrospinal fluid.[J] J Neurol Sci.1997;151:185-188.
[111]Rasmusson AM, Hauger RL, Morgan CAJ. at al. Low Baseline and Yohimbine-Stimulated Plasma Neuropeptide Y (NPY) Levels in Combat-Related PTSD[J]. BIOL PSYCHIATRY.2000;47:526-539.
[112]Furukawa T A, Konno W, Morinobu S, et al. Course and outcome of depressive episodes:Comparison between bipolar, unipolar and subthreshold depression. [J]Psychiatry Research,2000;96(3):211-220.
[113]Mitchell P, Parker G, Jamieson K, et al. Are there any differences between bipolar and unipolar melancholia?[J] Journal of Affective Disorders,1992; 25(2): 97-106.
[114]Coryell W, Andreasen NC, Endicott J,et al. The significance of past mania or hypo mania in the course and outcome of major depression. [J] American Journal of Psychiatry,1987;144,309-315.
[115]Kessing LV, Mortensen PB. Recovery from episodes during the course of affective disorder:A case-register study. [J]Acta Psychiatrica Scandinavica, 1999; 100(4):279-287.
[116]Mitchell P, Wilhelm K, Parker G, et al. The clinical features of bipolar depression:A comparison with matched major depressive disorder patients. [J].Journal of Clinical Psychiatry,2001;62(3):212-216.
[117]Parker G, Roy K, Wilhelm K,et al. The nature of bipolar depression: Implications for the definition of melancholia.[J] Journal of Affective Disorders, 2000;59(3):217-224.
[118]Breslau N, Meltzer HY. Validity of subtyping psychotic depression: Examination of phenomenology and demographic characteristics. [J] American Journal of Psychiatry,1998;145,35-40.
[119]Perlis RH, Brown E, Baker RW,et al. Clinical Features of Bipolar Depression Versus Major Depressive Disorder in Large Multicenter Trials. [J]Am J Psychiatry 2006; 163(2):225-2
[2]Angst J. The emerging epidemiology of hypomania and bipolar Ⅱ disorder.[J].J Affect Disord 1998;50(2-3):143-51.
[3]Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020:Global Burden of Disease Study[J].The Lancet,1997;349 (9064):1498-1504.
[4]Benazzi, F. High frequency of bipolar spectrum in outpatients with depression. [J].Can. J. Psychiatry 2004;49,279-280.
[5]Hirschfeld RM, Calabresse JR,Weissman MM, et al. Screening for BPD in the community.[J]. J Clin Psychiatry 2003;64(1):53-59.
[6]Heilig M, Widerlov E. Neurobiology and clinical aspects of neuropeptide Y. [J].Crit Rev Neurobiol.1995;9(2-3):115-36.
[7]Adrian TE, Allen JM, Bloom SR, et al.Neuropeptide Y distribution in human brain.[J]. Nature 1983;306(5943):584-586.
[8]. Gerald C, Walker MW, Criscione L, et al. A receptor subtype involved in neuropeptide-Y-induced food intake. [J].Nature 1996;382(6587):168-171.
[9]Heilig M, Widerlov E. Neuropeptide Y:an overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses. [J].Acta Psychiatr Scand 1990;82(2):95-114.
[10]Flood JF, Hernandez EN, Morley JE. Modulation of memory processing by neuropeptide Y. [J].Brain Research 1987;421(1-2):280-90.
[11]Redrobe JP, Dumont Y, St-Pierre JA, Quirion R. Multiple receptors for neuropeptide Y in the hippocampus:putative roles in seizures and cognition.[J]. Brain Research.1999;848(1-2):153-66.
[12]Colmers WF, Bleakman D. Effects of neuropeptide Y on the electrical properties of neurons. [J].Trends in Neuroscience.1994;17(9):373-9.
[13]Vezzani A, Sperk G, Colmers WF. Neuropeptide Y:emerging evidence for a functional role in seizure modulation.Trends in Neuroscience.1999;22(1):25-30.
[14]Small CJ, Morgan DG, Meeran K, Heath MM, Gunn I, Edwards CM, et al. Peptide analogue studies of the hypothalamic neuropeptide Y receptor mediating pituitary adrenocorticotrophic hormone release. Proceedings of the National Academy of Science USA.1997;94(21):11686-91.
[15]Catzeflis C, Pierroz DD, Rohner-Jeanrenaud F,et al. Neuropeptide Y administered chronically into the lateral ventricle profoundly inhibits both the gonadotropic and the somatotropic axis in intact adult female rats. Endocrinology 1993;132(1):224-34.
[16]Hashimoto H, Onishi H, Koide S,et al.Plasma neuropeptide Y in patients with major depressive disorder.[J].Neurosci Lett.1996;216(1):57-60.
[17]Heilig M, Murison R.Intracerebroventricular neuropeptide Y suppresses open field and home cage activity in the rat[J].Regulatory Peptides.1987;19(3-4):221-231.
[18]Heilig M.Murison R.Intracerebroventricular neuropeptideY protects against stress-induced gastric erosion in the rat. [J].European Journal of Pharmacology.1987;137(1):127-129.
[19]Tong Y, Dumont Y, Shen SH, Quirion R. Comparative developmental profile of the neuropeptide Y Y1 receptor gene and protein in the rat brain. [J].Molecular Brain Research.1997;48(2):323-32.
[20]Dumont Y, Fournier A, St-Pierre S, et al. Differential distribution of neuropeptide Y1 and Y2 receptors in the rat brain. [J] European Journal of Pharmacology.1990;191(3):501-3.
[21]Dumont Y, Fournier A, St-Pierre S,et al.. Autoradiographic distribution of [1251] [Leu31,Pro34]PYY and [125I]PYY-3-36 binding sites in the rat brain evaluated with two newly developed Y1 and T2 receptor radioligands. [J].Synapse,1996; 22(2):139-58.
[22]Kerkerian-Le Goff L, Forni C, et al. Intracerebroventricular administration of neuropeptide Y affects parameters of dopamine, glutamate and GABA activities in the rat striatum.[J]. Brain Res Bull.1992;28(2):187-193.
[23]Drumheller A, Bouali SM, Fournier A,et al. Neurochemical effects of neuropeptide Y (NPY) and NPY2-36.[J] Neuropeptides.1994;27(5):291-296.
[24]Gruber SH, Nomikos GG, Mathe AA. D-Amphetamine-induced increase in neurotensin and neuropeptide Y outflow in the ventral striatum is mediated via stimulation of dopamine D1 and D2/3 receptors.[J] J Neurosci Res.2002;69(1):133-139.
[25]Gruber SH, Mathe AA. Effects of typical and atypical antipsychotics on neuropeptide Y in rat brain tissue and microdialysates from ventral striatum.[J].J Neurosci Res.2000;61(4):458-463.
[26]Widerlov E, Lindstrom LH, Wahlestedt C, et al. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively [J]. Journal of Psychiatric Research.1988;22(1),69-79.
[27]Nikisch G, Mathe AA. CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy [J].European Psychiatry,2008; 23(5):356-359.
[28]Heilig M, Olof Zachrisson O, Thorsell A,et al. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism[J] Journal of Psychiatric Research,2004,38(2):113-121
[29]侯彩兰 贾福军 陈佐明等。重性抑郁症患者脑脊液中P物质、神经肽Y、5-羟色胺及去甲肾上腺素含量的研究[J].中华精神科杂志.2005；38(4)：199-201
[30]Widdowson PS, Ordway GA, Halaris AE. Reduced neuropeptide Y concentrations in suicide brain. [J].Neurochem.1992;59(1):73-80.
[31]Berrettini WH, Doran AR, Kelsoe J,,et al. Cerebrospinal fluid neuropeptide Y in depression and schizophrenia. [J].Neuropsychopharmacology.1987;1(1):81-83.
[32]Ordway GA, Stockmeier CA, Meltzer HY, et al. Neuropeptide Y in frontal cortex is not altered in major depression[J]. Journal of Neurochemistry.1995; 65(4):1646-1650.
[33]Frisch C, HankeJ, Kleineruschkamp S,et al. Positive correlation between the density of neuropeptide Y positive neurons in the amygdala and parameters of self-reported anxiety and depression in mesiotemporal lobe epilepsy patients. [J].Biol. Psychiatry.2009;66(5):433-440.
[34]Morgan CA, Rasmusson AM, Wang S, et al.NeuropeptideY, cortisol, and subjective distress in humans exposed to acute stress:replication and extension of previous report.[J] Biol. Psychiatry.2002;52 (2):136-142.
[35]Larsen PJ, Kristensen P. The neuropeptide Y (Y4) receptor is highly expressed in neurones of the rat dorsal vagal complex.[J] Brain Res. Mol. Brain Res.1997;48(1): 1-6
[36]Hashimoto H, Onishi H,Koide S, et al. Plasma neuropeptide Y in patients with major depressive disorder[J]. Neuroscience Letters.1996;216 (1):57-60
[37]陈松芳,吴志鹏,邵胜等。氟西汀对抑郁症患者血浆中P物质和神经肽Y的影响。[J]安徽医药.2008；12(7)：641-642
[38]杨斌,王有德,叶兰仙等。抑郁症患者血浆神经肽Y含量变化及其影响因素[J]中国临床康复.2006；10(46)：106-108
[39]Westrin A, Ekman R,skman-Bend L. Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y(NPY) plasma levels in mood disorder patients with a recent suicide attempt [J].European Neuropsychopharmacology.1999;9 (3):205-211
[40]Held K, Antonijevic I, Murck H, et al.Neuropeptide Y (NPY) shortens sleep latency but does not suppress ACTH and cortisol in depressed patients and normal controls[J].Psychoneuroendocrinology,2006; 31(1):100-107.
[41]Antonijevic IA, Murck H, Bohlhalter S, et al. Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men[J].Neuropharmacology,2000; 39(8):1474-1481.
[42]Sjoholm LK, Melas PA, Forsell Y, et al. PreproNPY Pro7 protects against depression despite exposure to environmental risk factors[J].Journal of Affective Disorders,2009;118,(1-3):124-130.
[43]Czermak C, Hauger R, Drevets WC, et al. Plasma NPY concentrations during tryptophan and sham depletion in medication-free patients with remitted depression [J].Journal of Affective Disorders,2008;110(3):277-281.
[44]Nilsson C, Karlsson G, Blennow K, et al. Differences in the neuropeptide Y-like immunoreactivity of the plasma and platelets of human volunteers and depressed patients.[J] Peptides.1996;17(3):359-62..
[45]Nikisch G., Agren H., Eap CB.,et al. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram [J].Int. J. Neuropsychopharmaco 1.2005; 8,(3):403-410.
[46]Widerlov, E., Heilig, M., Ekman, R., et al. Possible relationship between neuropeptide Y (NPY) and major depression:evidence from human and animal studies Nordic.[J]J. Psychiatry.1988;42,131-137.
[47]Olsson A., Regnell G, Traskman-Bendz L,et al. Cerebrospinal neuropeptide Y and substance P in suicide attempters during long-term antidepressant treatment.[J]. Eur. Neuropsychopharmacol.2004; 14(6):479-485.
[48]Redrobe JP, DumontY, Fournier,A, et al. Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test.[J]. Peptides.2005;26(8):1394-1400.
[49]Ishida H, Shirayama Y, Iwata M,et al.Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor. Hippocampus 2007;17(4):,271-280.
[50]Ruohonen ST, Savontaus E, Rinne P, et al. Stress-induced hypertension and increased sympathetic activity in mice overexpressing neuropeptide Y in noradrenergic neurons.[J] Neuroendocrinology.2009;89(3):,351-360.
[51]Jimenez-Vasquez PA, Zaida Diaz-Cabiale Z, Caber lotto L,et al.Electroconvulsive stimuli selectively affect behavior and neuropeptide Y (NPY) and NPY Y1 receptor gene expressions in hippocampus and hypothalamus of Flinders Sensitive Line rat model of depression [J] European neuropsychopharmacology.2007;17(4):298-308
[52]Obuchowicz E, Krysiak R, Herman ZS. Does neuropeptide Y (NPY) mediate the effects of psychotropic drug[J].Neuroscience and Biobehavioral Reviews.2004;28(6):595-610
[53]Kuromitsu J, Yokoi A, Kawai T, et al.Reduced neuropeptide Y mRNA levels in the frontal cortex of people with schizophrenia and bipolar disorder [J].Gene Expression Patterns.2001;1(1):17-21
[54]Caberlotto L, Hurd YL, Neuropeptide Y Y(1) and Y(2) receptor mRNA expression in the prefrontal cortex of psychiatric subjects. Relationship of Y(2) subtype to suicidal behavior. [J].Neuropsychopharmacology.2001;25(1):91-97.
[55]Zachrisson O, Mathe'AA, Stenfors C, et al. Region-specific effects of chronic lithium administration on neuropeptide Y and somatostatin mRNA expression in the rat brain. [J]Neurosci Lett 1995;194 (1-2):89-92.
[56]Harrison S, Geppetti P. Substance P. [J]. International Journal of Biochemistry and Cell Biology.2001;33,555-576.
[57]Ribeiro-da-Silva A, Hokfelt T. Neuroanatomical localisation of substance P in the CNS and sensory neurons. [J].Neuropep tides.2000;34 (5):256-271
[58]Richard Hargreaves. Imaging substance P recep tors(NK1) in the living human brain using positron emission tomography. [J]J clin Psychiatry,2002;63 (supp 111): 18-24
[59]Sergeyev V, Hokfelt T, Hurd Y. Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. [J].NeuroReport.1999;10(18):3967-3970.
[60]Hahn MK, Bannon MJ. Stress-induced C-fos expression in the rat locus coeruleus is dependent on neurokinin 1 receptor activation. [J]. Neuroscience.1999;94(4):1183-1188.
[61]Otsuka M., Yoshioka K. Neurotransmitter functions of mammalian tachykinins. [J]Physiol. Rev.1993;73 (2):229-308.
[62]Lieb K, Ahlvers K, Dancker K, et al. Effects of the neuropeptides substance P on sleep, mood, and neuroendocrine measures in healthy young men. [J].Neurop sychopharmacology.2002;27 (6):1041-1049
[63]Andersen ML, Nascimento DC, Machado RB et al. Sleep disturbance induced by substance P in mice[J] Behavioural Brain Research.2006; 167(2):212-218
[64]Teixeira, R.M., Santos A RS, Ribeiro SJ, et al. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behaviour in mice. [J].Eur. J. Pharmacol.1996;311(1):7-14
[65]Krase,W, Michael K,Hans-Ulrichet S. Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats. [J]Behav. Brain Res. 1994;63(1):81-88
[66]Kramer, M.S. Cutler N, Feighner J,et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors.[J]. Science.1998;281(5383): 1640-1645.
[67]Rupniak, N.M. et al. Comparison of the phenotype of NK1R-/-mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. [J]Behav. Pharmacol.2001;12(6-7):497-508
[68]Papp M, Vassout A, Gentsch C. The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats.[J]. Behav. Brain Res.2000; 115(1):19-23
[69]Varty, G.B.Cohen-willians ME,Morgan CA, et al.. The gerbil elevated plus-maze Ⅱ:anxiolytic-like effects of selective neurokinin NK1 receptor antagonists [J]Neuropsychopharmacology.2002; 27(3):371-379
[70]Rimon R., Greves L P., Nyberg, F., et al.. Elevation of substance P-like peptides in the CSF of psychiatric patients.[J]. Biological Psychiatry 1984,19(4):509-516.
[71]Geracioti TD, Carpenter LL, Owens, M.J, et al. Elevated cerebrospinal fluid substance P concentrations in post-traumatic stress disorder and major depression. [J] American Journal of Psychiatry.2006; 163 (4):637-643.
[72]Bondy B, Baghai TC, Minov C, et al. Substance P Serum Levels Are Increased in Major Depression:Preliminary Results[J].BIOLPSYCHIATRY.2003;53(6):538-542.
[73]Deuschle M, Peter Sander P, Inga Herpfer H, et al.Substance P in serum and cerebrospinal fluid of depressed patients:No effect of antidepressant treatment.[J]. Psychiatry Research.2005;136(1):1-6
[74]Carpenter LL, Bayat L, Moreno F, et al. Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy[J] Psychiatry Research. 2008;157(1-3):123-129
[75]Shirayama Y, Mitsushio H., Takashima M., et al. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat.[J].Brain Research.1996; 739(1-2):70-78.
[76]Martensson B, Nyberg S, Toresson G.,et al. Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid. [J] Acta Psychiatrica Scandinavica.1989;79(6):586-596.
[77]Lieb K,Walden J,Grunze H, et al. Serum levels of substance P and response to antidepressant pharmacotherapy. [J].Pharmacopsychiatry.2004;37(5):238-239.
[78]Burnet PW, Harrison PJ. Substance P (NK1) redeptors in the cingulate cortex in unipolar and biopolarmood disorder and schizophrenia. [J].Biol p sychiatry.2000;47 (1):80-83
[79]Freed AL, Audus KL, Lunte SM. Investigation of substance P transport across the blood-brain barrier. [J]Peptides.2002;23(1):157-165.
[80]Dunner DL. Clinical consequences of under-recognized bipolar spectrum disorder.[J].J Bipolar Disord.2003;5(6):456-464.
[81]Post RM, Leverich GS, NolenWA, et al. A reevaluation of the role of antidepressants in the treatment of bipolar depression:data from the Stanley Foundation Bipolar Network.[J] Bipolar Disord.2003;5(6):396-406.
[82]Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major dep ression and bipolar disorder [J]. JAMA,1996;276 (4):293-299.
[83]Benazzi F. Symptoms of depression as possible markers of bipolar Ⅱ disorder [J]. Prog Neurop sychopharmacol Biol Psychiatry,2006;30 (3):471-477.
[84]Weissman, M.M., Bland, R.C., Canino, GJ. Cross-sectional epidemiology of major depression and bipolar depression. [J] JAMA:The Journal of the American Medical Association.1996.;276 (4):293-299.
[85]Benazzi F. Challenging the unipolar-bipolar division:Does mixed depression bridge the gap? [J]. Neuro-Psychopharmacology & Biological Psychiatry.2007;31 (1):97-103.
[86]National Institute of Mental Health (NIMH). (1998). Genetics and mental disorders:Report of the NIMH genetics workgroup.Bethesda, MD7'NIMH publication number NIH-98-4268.
[87]Benazzi F. Family history validation of a definition of mixed depression[J]. Comprehensive Psychiatry.2005;46,(3):159-166
[88]Emilien G, Septien L, Brisard C, et al. Bipolar disorder:How far are we from a rigorous definition and effective management?[J] Neuro-Psychopharmacology & Biological Psychiatry.2007;31 (5):975-996.
[89]KelsoeJ R. Arguments for the genetic basis of the bipolar spectrum. [J].Journal of Affective Disorders.2003;73,(2):183-197.
[90]Benazzi F. Symptoms of depression as possible markers of bipolarⅡ disorder [J]. Prog Neurop sychopharmacology Biol Psychiatry.2006; 30 (3):471-477.
[91]Serretti A, Mandelli L, Lattuada E,et al. Clinical and demographic features of mood disorder subtypes.[J]. Psychiatry Res.2002;112(3):195-210.
[92]Baethge C, Baldessarini RJ, Freudenthal K, et al. Hallucinations in BPD: characteristics and comparison to unipolar depression and schizophrenia.[J]. Bipolar Disord.2005;7(2):136-45.
[93]Goldberg J F, Perlis R H, Bowden C L, et al. Manic Symptoms During Depressive Episodes in 1,380 Patients With Bipolar Disorder:Findings From the STEP-BD[J].Am J Psychiatry.2009;166(2):173-181.
[94]Benazzi F. Mixed dep ression:a clinicalmarker of bipolar-Ⅱ disorder [J]. Prog Neurop sychopharmacology Biol Psychiatry.2005;29 (2):267-274.
[95]Videbech P. PET measurements of brain glucose metabolism and blood flow in major depressive disorder:A critical review. [J] Acta Psychiatrica Scandinavica, 2000;101(1):11-20.
[96]Yurgelun-Todd DA, Gruber SA, Kanayama G.,et al. fMRI during affect discrimination in bipolar affective disorder. [J].Bipolar Disorders,2000;3,237-248.
[97]Koslow SH, Maas JW, Bowden CL,et al. CSF and urinary biogenic amines and metabolites in depression and mania. A controlled, univariate analysis. [J]Archives of General Psychiatry,1983;49(9),999-1010.
[98]Asberg M., Bertillsson L, Martensson B,et al. CSF monoamine metabolites in melancholia.[J]. Acta Psychiatrica Scandinavica,1984;69(3):201-219.
[99]Altshuler LL., Curran JG, Hauser P, et al. T2 hyperintensities in bipolar disorder:Magnetic resonance imaging comparison and literature meta-analysis. [J]American Journal of Psychiatry,1995;152,1139-1144.
[100]Ackenheil M. Neurotransmitters and signal transduction processes in bipolar affective disorders:A synopsis. [J]Journal of Affective Disorders,2001;62(1): 101-111.
[101]Barbini B, Colombo C, Benedetti F, et al. The unipolar-bipolar dichotomy and the response to sleep deprivation.[J]. Psychiatry Research,1998; 79(1):43-50.
[102]American Psychiatric Association,1994. Diagnostic and Statistical Manual of Mental Disorders,4th ed. American Psychiatric Association, Washington, DC.
[103]LecrubierY, Sheehan D,Weiller E,et al. The MINI International Neuropsychiatric terview (M.I.N.I.) a short diagnostic structured interview:reliability and validity according to the CIDI.[J]Eur Psychiatry,1997,12:224-231
[104]司天梅；舒良；党卫民等。简明国际神经精神访谈中文版的临床信效度。[J]中国心理卫生杂志.2009；23(7)：493-497.
[105]赵靖平；郑延平.Hamilton抑郁量表的信度和效度.[J]中国心理卫生杂志,1992：6(5)： 214-216
[106]Hirschfeld RMA,Williams JBW, Calabrese JR, et al. Development and validation of a screening instrument for bipolar spectrum disorder:The mood disorder questionnaire[J]. Am J Psychiatry,2000;157:1873-1875.
[107]杨海晨,廖春平,苑成梅等.中文版心境障碍问卷在双相Ⅰ型障碍中的应用[J].临床精神医学杂志.2009；9(1)：19-21.
[108][Ka-Fai Chung, Kwok-Chu Tso, Robert Ting-Yiu Chung.Validation of the Mood Disorder Questionnaire in the general population in Hong Kong[J] Comprehensive Psychiatry,2009;50(5):471-476.
[109]Vieta E, Moreno JS, A. Bulbena A,et al. Cross validation with the mood disorder questionnaire (MDQ) of an instrument for the detection of hypomania in Spanish:The 32 item hypomania symptom check list (HCL-32)[J]. Journal of Affective Disorders,2007;101(1-3):43-55
[110]Dotsch, Adelmann J, Englaro P, et al. Relation of leptin and neuropeptide Y in human blood and cerebrospinal fluid.[J] J Neurol Sci.1997;151:185-188.
[111]Rasmusson AM, Hauger RL, Morgan CAJ. at al. Low Baseline and Yohimbine-Stimulated Plasma Neuropeptide Y (NPY) Levels in Combat-Related PTSD[J]. BIOL PSYCHIATRY.2000;47:526-539.
[112]Furukawa T A, Konno W, Morinobu S, et al. Course and outcome of depressive episodes:Comparison between bipolar, unipolar and subthreshold depression. [J]Psychiatry Research,2000;96(3):211-220.
[113]Mitchell P, Parker G, Jamieson K, et al. Are there any differences between bipolar and unipolar melancholia?[J] Journal of Affective Disorders,1992; 25(2): 97-106.
[114]Coryell W, Andreasen NC, Endicott J,et al. The significance of past mania or hypo mania in the course and outcome of major depression. [J] American Journal of Psychiatry,1987;144,309-315.
[115]Kessing LV, Mortensen PB. Recovery from episodes during the course of affective disorder:A case-register study. [J]Acta Psychiatrica Scandinavica, 1999; 100(4):279-287.
[116]Mitchell P, Wilhelm K, Parker G, et al. The clinical features of bipolar depression:A comparison with matched major depressive disorder patients. [J].Journal of Clinical Psychiatry,2001;62(3):212-216.
[117]Parker G, Roy K, Wilhelm K,et al. The nature of bipolar depression: Implications for the definition of melancholia.[J] Journal of Affective Disorders, 2000;59(3):217-224.
[118]Breslau N, Meltzer HY. Validity of subtyping psychotic depression: Examination of phenomenology and demographic characteristics. [J] American Journal of Psychiatry,1998;145,35-40.
[119]Perlis RH, Brown E, Baker RW,et al. Clinical Features of Bipolar Depression Versus Major Depressive Disorder in Large Multicenter Trials. [J]Am J Psychiatry 2006; 163(2):225-2